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PAI-1 mRNA by in situ hybridization. Glomerular and tubularPeroxisome proliferator-activated receptor-g agonist troglita-
transforming growth factor-b (TGF-b) mRNA expression waszone protects against nondiabetic glomerulosclerosis in rats.
decreased with TGL treatment. Glomerular macrophages,Background. Peroxisome proliferator-activated receptor-g
present in CONT and TRX rats, did not express PPARg, in(PPARg) is a member of the nuclear receptor superfamily of
contrast to PPARg 1 macrophages in control carotid arteryligand-dependent transcriptional factors with beneficial effects
in diabetes mediated by improved insulin sensitivity and lipid plaque. PPARg was expressed in resident cells.
metabolism, but potential adverse effects in atherosclerosis by Conclusions. Our results demonstrate in vivo that the PPARg
promoting in vitro foam cell formation. We explored whether ligand TGL ameliorates the progression of glomerulosclerosis
a PPARg agonist, troglitazone (TGL), affects sclerosis by in a nondiabetic model. Macrophages show phenotypic diver-
mechanisms unrelated to insulin and lipid effects in a model sity in glomerular versus vascular sclerosis, with macrophage
of nondiabetic glomerulosclerosis. PPARg expression in only the latter. PPARg beneficial effects
Methods. Adult male Sprague Dawley rats underwent 5/6 are independent of insulin/glucose effects and are associated
nephrectomy and were treated for 12 weeks as follows: control with regulation of glomerular cell proliferation, hypertrophy,
(CONT), no further treatment; triple antihypertensive therapy and decreased PAI-1 and TGF-b expression.
(TRX); and TGL or TGL 1 TRX. Functional, morphological,
and molecular analyses were performed.
Results. Systolic blood pressure (SBP) was increased in
Insulin resistance has been highlighted as a commonCONT and TGL groups (161 6 1 and 160 6 3 mm Hg), but
not in TGL 1 TRX and TRX (120 6 3 vs. 126 6 1 mm Hg, causal factor for hypertension, diabetes mellitus, and
P , 0.0001 vs. non-TRX). Serum triglyceride and cholesterol obesity and is the underlying defect in a distinct clinical
levels in all groups remained normal except for slightly higher entity defined as metabolic syndrome X [1, 2]. Treatmentserum cholesterol levels in TRX group. TGL groups had re-
of this insulin resistance has great therapeutic potentialduced proteinuria, serum creatinine, and glomerulosclerosis
for the control of type II diabetes. Troglitazone (TGL)versus CONT, in contrast to no significant effect with TRX
alone (sclerosis index, 0 to 41 scale: CONT 1.99 6 0.42, TGL was the first marketed example of a novel therapeutic
0.85 6 0.12, TGL 1 TRX 0.56 6 0.14, TRX 1.30 6 0.21; TGL, class of antidiabetic agents, the thiazolidinediones
P , 0.05; TGL 1 TRX, P 5 0.01 vs. CONT). Glomerular (TZDs), for the treatment of type 2 diabetes. As a class,cell proliferation, assessed by proliferating cell nuclear antigen
TZDs (TGL, rosiglitazone, and pioglitazone) have been(PCNA), was decreased after treatment with TGL or TGL 1
shown to exert antihyperglycemic and antihyperinsulin-TRX, in parallel with decreases in glomerular p21 mRNA and
p27 protein compared with CONT and TRX (PCNA 1 cells/ emic actions in laboratory animal models of insulin resis-
glomerulus: CONT 2.04 6 0.64, TGL 0.84 6 0.21, TGL 1 TRX tance and diabetes [3–7] and in humans [8–10]. Clinically,
0.30 6 0.07, TRX 1.38 6 0.37; TGL, P , 0.05, TGL 1 TRX, P ,
these actions result in a reduction in fasting hyperglyce-0.01 vs. CONT). Glomerular plasminogen activator inhibitor-1
mia without an increase in plasma insulin levels. In addi-(PAI-1) immunostaining was decreased in TGL or TGL 1
TRX groups (0 to 41 scale, CONT 2.42 6 0.32, TGL 1.40 6 tion to their antihyperglycemic effect, TZDs also reduce
0.24, TGL 1 TRX 1.24 6 0.17, TRX 2.53 6 0.24; TGL or circulating levels of triglycerides (TGs) and free fatty
TGL 1 TRX vs. CONT, P , 0.05), with a parallel decrease in acids (FFAs) [7].
Recent evidence indicates that the peroxisome prolif-
erator-activated receptor-g (PPARg) is the molecularKey words: cell turnover, plasminogen activator inhibitor-1, macro-
phage, p21, p27. target of the TZDs [11, 12]. PPARg is a member of the
nuclear receptor superfamily of ligand-activated tran-
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arachidonic acid metabolites derived from the cyclooxy- glomerulosclerosis in a model of nondiabetic vascular
injury. Furthermore, we have linked this protective effectgenase pathway, such as 15-deoxy-D12,14-prostaglandin J2
(15-deoxy PGJ2) [14, 15]. Certain nonsteroidal anti- in sclerosis to decreased macrophage infiltration, de-
creased PAI-1 and transforming growth factor-b (TGF-b),inflammatory drugs (NSAIDs) are also identified as
PPARg ligands [16]. Following activation, PPARg heter- and regulation of glomerular cell growth.
odimerizes with retinoic X receptor (RXR) and binds
to peroxisome proliferator response elements (PPREs)
METHODS
in the promoter region of target genes, thereby regulat-
Experimental design and animalsing their transcription [17].
Recent advances in the understanding of the biology Adult male Sprague Dawley rats (250 to 300 g; Charles
River, Nashville, TN, USA) were studied. Rats wereof the PPARs suggest a major role for PPARg in the
regulation of adipocyte differentiation and the expres- housed under normal conditions with a 12-hour light/
dark cycle at 708F with 40% humidity and 12 air ex-sion of adipocyte-specific genes and of key regulatory
genes involved in carbohydrate and lipid metabolism changes per hour and received standard rat powdered
diet (Purina Rodent “5001” meal, 23.4% protein, 4.5%[18–20]. Although adipose tissues have been recognized
as a principal site of expression of PPARg, these recep- fat, 6.0% fiber, 0.40% sodium; Tusculum Feed Center,
Nashville, TN, USA) and water. Rats underwent 5/6tors are also expressed at low levels in many other tissues
and cell types and may play important roles in nonadi- nephrectomy (Nx) by right Nx and ligation of two or
three main branches of the left renal artery by silk liga-pose sites [20, 21].
One of the earliest steps in the formation of atheroscle- ture to remove approximately 5/6 renal mass. The sur-
gery was performed under anesthesia with sodium pento-rotic lesions is the conversion of macrophages to choles-
terol-engorged foam cells [22]. The formation of foam barbital (50 mg/kg body wt, IP). The Nx rats were then
divided into four groups as follows: The control groupcells is characterized by dramatic changes in the cells’
lipid metabolism, including increased expression of scav- (CONT, N 5 7) received normal rat chow powder as
described previously in this article. The triple-therapyenger receptors and uptake of oxidized low-density lipo-
protein (LDL). In vitro, PPARg promoted monocyte to group received antihypertensive drugs [TRX, N 5 7,
reserpine 5 mg/L drinking water (DW), hydralazine 80foam cell transformation and uptake of oxidized LDL
through transcriptional induction of scavenger receptors mg/L DW, and hydrochlorothiazide 25 mg/L DW]. This
dose, although normalizing systemic blood pressure inCD36 [23, 24]. Furthermore, in vivo PPARg was ex-
pressed at high levels in foam cells of human atheroscle- previous studies in this model, does not protect against
glomerulosclerosis [30, 31]. The TGL group receivedrosis lesions [25]. These observations suggested that
PPARg has potential adverse effects in atherosclerosis. TGL mixed with powdered chow (TGL, 500 mg/kg/day
body wt, N 5 7; kindly provided by Parke Davis, MorrisPeroxisome proliferator-activated receptor-g activa-
tion also can regulate other mediators of vascular lesions, Plains, NJ, USA). The dose of TGL was chosen based
on this dose correcting abnormal carbohydrate and lipidsuch as plasminogen activator inhibitor-1 (PAI-1). Vari-
able response of PAI-1 to PPARg activation was ob- metabolism in rats and mice with diabetes [7, 32, 33]. In
addition, these studies have shown that this dose resultsserved in in vitro studies in endothelial cells [26, 27].
Recent studies in mesangial cells in culture showed that in a plasma concentration of TGL comparable with that
achieved in clinical studies. The appropriate amount ofPAI-1 mRNA induction was decreased by PPARg ago-
nist (communication with S. Nicholas). TGL in chow in this study was regularly adjusted on the
basis of body weight. The last group received a combina-In vivo, beneficial effects of PPARg were demon-
strated in diabetic nephropathy and in the WHHL rabbit tion of TGL and antihypertensive therapy as discussed
previously in this article (TGL 1 TRX, N 5 7). Animalsmodel of atherosclerosis [28, 29]. Rosiglitazone, a PPAR
agonist, ameliorated development of injury in the Zucker were monitored (discussed later in this article) and sacri-
ficed at 12 weeks. Kidneys were harvested for analysisfatty rat model of type 2 diabetes. This effect was associ-
ated with reduced plasma glucose, total cholesterol, and of morphologic and molecular parameters.
TG levels [28]. The protective metabolic effects could,
Analysis of kidney functionhowever, mask potentially adverse effects on vascular
injury suggested by the previously mentioned studies. Systolic blood pressure (SBP) and 24-hour urinary
protein were assessed at weeks 4, 8, and 12. SBP wasWe thus hypothesized that analogous to the manifold
actions of angiotensin now recognized beyond vasocon- measured using tail-cuff plethysmography in unanesthe-
tized prewarmed trained rats at ambient temperature ofstriction, PPARg could have multiple effects beyond
lipid metabolism and insulin sensitization due to its ef- 298C. Animals were placed in metabolic cages for 24
hours for urine collection, and urine protein was mea-fects on transcription factors. Our results indeed show
that PPARg agonist protects against development of sured by Bio-Rad Protein Assay Kit (Bio-Rad Labora-
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tories, Hercules, CA, USA). Serum creatinine was mea- goat anti-rabbit Ig (BioGenex Laboratories) for 45 min-
sured by Vitros CREA slides (Johnson & Johnson utes, followed by peroxidase-conjugated streptavidin for
Clinical Diagnostics Inc., Rochester, NY, USA). 45 minutes. After rinsing with PBS, diaminobenzidene
was added as a chromagen. Slides were counterstained
Structural analyses with hematoxylin. The number of PCNA or p27-positive
Kidney tissue from rats was immersion fixed in 4% nuclei per glomerulus was counted. PAI-1 glomerular
paraformaldehyde/phosphate-buffered saline (PBS) so- expression was evaluated by a semiquantitative score.
lution and routinely processed, and 4 mm sections were Scores of 0 to 4 represent negative, trace, ,10%, 10 to
stained with periodic acid-Schiff and Masson’s tri- 25%, and .25% staining, respectively, in each glomeru-
chrome. Immunohistochemistry and in situ hybridization lus. Control slides treated with nonspecific antisera in-
studies were performed (discussed later in this article). stead of primary antibody showed no staining. All sec-
A semiquantitative score [sclerosis index (SI)] was tions were examined without the knowledge of the
used to evaluate the degree of glomerular sclerosis. The treatment protocol.
severity of sclerosis for each glomerulus was graded from
0 to 41 as follows: 0 represents no lesion; 11 represents Reverse transcriptase-polymerase chain reaction
sclerosis of ,25% of the glomerulus, while 21, 31, and Rat PPARg cDNA fragment comprising part of the
41 represent sclerosis of 25 to 50%, 50 to 75%, and A/B and DNA binding domains was generated by re-
.75% of the glomerulus, respectively. A whole kidney verse transcriptase-polymerase chain reaction (RT-
average SI was obtained by averaging scores from all PCR) using 10 mg of total RNA from 5/6 Nx rat kidney
glomeruli on one section. Tubulointerstitial fibrosis was tissue. The specific primers were directed against the rat
evaluated qualitatively on Masson’s trichrome-stained sequences for PPARg: 59-GAG ATG GAA TTC TGG
section. All sections were examined without knowledge CCC ACC AAC TTC GG-39 (sense) and 59-TAT CAT
of the treatment protocol. AAA TAA GCT TCA ATC GGA TGG TTC-39 (anti-
sense). Total RNA was extracted by RNAzole B methodSerum cholesterol and triglyceride analysis
(Tel-Test, Inc., Friendswood, TX, USA) and reverse
Serum cholesterol levels were determined using transcribed to single-stranded cDNAs using Super-
Raichem reagent no. 80035 (Raichem, San Diego, CA, scripte II reverse transcriptase (GIBCO BRL, Gaithers-
USA), adapted for a microtiter plate assay [34]. Briefly, burg, MD, USA) and 100 mmol/L oligo dT according
100 mL of a 1:100 dilution of serum were mixed with 100 to the manufacturer’s instructions (GIBCO BRL). The
mL of reagent and incubated at 378C for 10 minutes in
cDNA was then amplified using PPARg-selective prim-
a microtiter plate. The 490 nm absorbance was read
ers. PCR reactions were carried out in 10 mmol/L TrisCl,on a Molecular Devices microplate reader (Molecular
50 mmol/L KCl, 2.5 mmol/L MgCl2, 0.2 mmol/L dNTPs,Devices, Menlo Park, CA, USA). Serum TG levels were
and 1 mmol/L primers at 958C for one minute, 558C fordetermined using Sigma kit no. 339 (Sigma, St. Louis,
two minutes, and 728C for one minute for 35 cycles in aMO, USA) similarly adapted for microtiter plate assay.
thermal cycler followed by an extension step at 728C for
seven minutes. After amplification, a 403 bp long PPARgImmunostaining of PCNA, p27, and PAI-1
cDNA was sequenced and subcloned in PCRII vectorFour micrometer sections from tissue fixed overnight
(Invitrogen, Carlsbad, CA, USA). The first-strand cDNAat 48C with paraformaldehyde were dewaxed, dehydrated,
of human p27 was made from 10 mg of total RNA fromtreated by 3% hydrogen peroxidase for 10 minutes, and
normal human kidney tissue. The reverse transcriptionexposed to Power Block (BioGenex Laboratories, San
process followed the same protocol as described pre-Ramon, CA, USA) for 45 minutes. Proliferating cells
viously in this article. The gene-specific primers for hu-were identified in rat kidney by proliferating cell nuclear
man p27 were 59-CCT CTT CGG CCC GGT GGA C-39antigen (PCNA) cyclin polypeptide immunohistochem-
(sense, in the coding region from nucleotide 93 to 111)istry. For PCNA staining, monoclonal mouse anti-human
and 59-TCT GCT CCA CAG AAC CGG C-39 (anti-PCNA (Dako Corporation, Carpinteria, CA, USA) was
sense, in the coding region from nucleotide 541 to 559)applied and incubated for 30 minutes at room tempera-
[36]. PCR reactions were carried out at 958C for oneture followed by rabbit anti-mouse antibody (Dako) for
minute, 628C for two minutes, and 728C for one minute30 minutes. For detection of p27, goat anti-rat p27 poly-
for 35 cycles in a thermal cycler followed by an extensionclonal antibody (Santa Cruz Biotechnology Inc., Santa
step at 728C for seven minutes. After amplification, aCruz, CA, USA) was added, incubated for 60 minutes,
467 bp long p27 cDNA was sequenced and subclonedfollowed by rabbit anti-goat antibody (Dako) for 30 min-
in PCRII vector (Invitrogen). A 420 bp length cDNAutes. For PAI-1 staining, sections were incubated with
fragment specific for human p21 in the coding regionrabbit anti-rat PAI-1 antibody (American Diagnostica
Inc., Greenwich, CT, USA) overnight [35], biotinylated was amplified by RT-PCR and subcloned into a vector
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Fig. 1. Systolic blood pressure (SBP) changes after 5/6 nephrectomy
(Nx). SBP in the control (CONT; j) and troglitazone (TGL; d) groups
increased over 12 weeks, contrasting normal SBP in groups receiving
triple antihypertensive drug therapy (TRX; r) or TGL 1 TRX (m). Fig. 2. Urine protein excretion after 5/6 Nx. Urine protein excretion
increased in CONT (j) and TRX (r) groups. TGL (d) alone or TGL 1
TRX (m) treatment for 12 weeks significantly reduced proteinuria (*P ,
0.01, TGL or TGL 1 TRX vs. CONT).
[pBlueScript SK(2); Stratagene, La Jolla, CA, USA]
[37].
swine anti-rabbit IgG (Dako) as secondary and tertiaryIn situ hybridization
antibodies and finally developed with diaminobenzidine[35S]-labeled sense and antisense riboprobes for PAI-1
(DAB) as chromagen. Macrophages were detected withand TGF-b were prepared as previously described
mouse monoclonal antibody ED1 (1:50; Dako), followed[38, 39]. [35S]-labeled sense and antisense riboprobes for
by biotinylated goat anti-mouse IgG (Innogenex, SanPPARg and p27 were prepared by transcription of the
Ramon, CA, USA) for 30 minutes and alkaline phospha-pCRe II plasmid (Invitrogen), and [35S]-labeled sense
tase-streptavidin conjugate (Innogenex) for 30 minutes.and antisense riboprobes for p21 were prepared by tran-
Sections were developed with fast red TR/Naphtol AS-scription of the pBlueScript SK(2) plasmid [37] with
MX (Sigma) for five minutes and then counterstainedinsertion of each responding cDNA fragment by SP6 or
and coverslipped. Negative control with nonspecific se-T7 RNA polymerase (Ambion, Austin, TX, USA). In
rum from the species of primary antibody instead ofsitu hybridization was performed as previously described
specific antibody showed no staining. Transitional epi-[36]. Briefly, sections were treated with proteinase K and
thelial cells of the pelvis were used as positive controlstriethanolamine/acetic anhydride, and hybridization was
for PPARg staining. Human carotid artery plaques weredone at 508C. Sections were washed in buffer with 5 3
also double stained with antibody to CD68 (Dako) andstandard saline citrate (SSC) and 20 mmol/L b-mercapto-
antibody to PPAR-g.ethanol at 508C for 15 minutes, then washed in 2 3 SSC,
50% formamide at 688C for 20 minutes, in TEN twice
Statistical analysisat 378C for 10 minutes, treated with RNase at 378C for
Results are expressed as mean 6 SEM. Statistical dif-30 minutes, washed in TEN at 378C for 10 minutes, and
ference was assessed by a single-factor variance (analysisincubated twice in 2 3 SSC and 0.1 3 SSC at 688C for
of variance, ANOVA) followed by unpaired t test as15 minutes. Sections were then dehydrated in ethanol
appropriate. Nonparametric data were compared byand air dried, dipped in photographic emulsion, and ex-
Mann–Whitney U-test. A P value , 0.05 was consideredposed at 48C for 10 days. The sections were developed
to be significant.with D-19 developer (Eastman Kodak, Rochester, NY,
USA) and counterstained with toluidine blue. Negative
control in situ hybridizations were done with sense probes. RESULTS
Body and renal functional changesDouble immunostaining
Body weights of rats in each group (N 5 7 each group)Peroxisome proliferator-activated receptor-g immu-
increased over time, although treated rats gained lessnostaining was performed with primary mouse mono-
than control (at 12 weeks after 5/6 Nx, CONT 407 6 20,clonal antibodies to human PPARg (Santa Cruz Biotech-
TGL 372 6 12, TGL 6 TRX 327 6 8, TRX 358 6 10nology, Inc.), followed by peroxidase conjugated rabbit
anti-mouse IgG (Dako) and peroxidase-conjugated g, CONT vs. treated groups P # 0.05). SBP was increased
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Fig. 3. Renal injury at 12 weeks after 5/6 Nx. TGL alone or TGL 1 TRX treatment for 12 weeks significantly decreased glomerulosclerosis versus
control (E). Glomerulosclerosis, tubular atrophy, and interstitial fibrosis were present in CONT (A) and TRX (B) rats; treatment with TGL (C)
or TGL 1 TRX (D) for 12 weeks decreased glomerulosclerosis (PAS stain, 3100).
significantly in untreated control rats by four weeks after Lipid levels
5/6 Nx (150 6 5 vs. baseline 122 6 3 mm Hg, P , 0.0001) At 12 weeks after 5/6 Nx, serum TG and cholesterol
and continued to increase slightly until 12 weeks (Fig. levels in all groups were comparable and remained in
1). Interestingly, TGL did not reduce SBP (at 12 weeks the normal range except for a significantly higher serum
160 6 3 vs. CONT 161 6 1 mm Hg, P 5 NS). SBP in cholesterol level in the TRX group (serum TG, CONT
TRX and TGL 1 TRX groups remained normal (TRX 89 6 9, TGL 134.1 6 10.4, TGL 6 TRX 110.5 6 17.8,
126 6 1, TGL 1 TRX 120 6 3 mm Hg, P , 0.0001 vs. TRX 112.5 6 31.6 mg/dL, P 5 NS; serum cholesterol,
CONT or TGL, respectively; Fig. 1). Urinary protein CONT 122.9 6 5.4, TGL 130.1 6 6.7, TGL 6 TRX 129.4 6
excretion was dramatically increased in CONT rats by 13.1, TRX 161.5 6 14.6 mg/dL, TRX vs. CONT, P # 0.05).
four weeks after 5/6 Nx (120.9 6 15.3 vs. baseline 12.0 6
Cellular proliferation1.4 mg/24 h, P , 0.0001) and continued to increase (at
12 weeks 213.4 6 29.1 mg/24 h, P , 0.0001 compared Immunostaining for PCNA was negative in the normal
with baseline). TRX did not affect the course of protein- rat glomerulus (data not shown). In CONT rats, PCNA-
uria (P 5 NS vs. CONT). In contrast, TGL alone or in positive cells were present in glomeruli and tubules. Glo-
combination with TRX significantly reduced proteinuria merular visceral and parietal epithelial cells, mesangial,
at 4, 8, and 12 weeks (Fig. 2). At 12 weeks after 5/6 and endothelial cells showed occasional PCNA staining.
Nx, serum creatinine was increased in CONT and TRX Glomerular PCNA positivity was dramatically decreased
groups; TGL and TGL 1 TRX treatment decreased after treatment with TGL or TGL 1 TRX, but not after
serum creatinine levels compared with CONT (serum TRX alone (Fig. 4).
creatinine: CONT 3.0 6 0.7, TGL 1.6 6 0.2, TGL 1
p21 and p27 expressionTRX 1.0 6 0.04, TRX 2.0 6 0.4 mg/dL; TGL or TGL 1
TRX vs. CONT, P , 0.05). Glomerular p21 mRNA expression, primarily in vis-
ceral epithelial cells, was increased in CONT (Fig. 5A)
Renal morphological changes and TRX rats (data not shown) compared with baseline
In untreated CONT rats and TRX rats, glomeruloscle- levels in TGL (Fig. 5B). Glomerular p27 mRNA was
rosis, tubular atrophy, dilation, and interstitial fibrosis expressed at a diffuse, low level, similar in all groups
were present. TRX, as expected, had no significant effect (Fig. 5 C, D). p27 protein expression was up-regulated
on glomerulosclerosis (SI, 0 to 4 scale: CONT 1.99 6 in glomeruli in CONT (Fig. 5E) and TRX rats (data not
0.42 vs. TRX 1.30 6 0.21, P 5 NS) [30, 31]. Both TGL shown); treatment with TGL (Fig. 5F) or TGL 1 TRX
alone and TGL 1 TRX significantly ameliorated the (data not shown) decreased the p27 protein expression.
development of glomerulosclerosis compared with con-
PAI-1 mRNA and protein expressiontrol (CONT 1.99 6 0.42 vs. TGL 0.85 6 0.12, P , 0.05,
vs. TGL 1 TRX 0.56 6 0.14, P 5 0.01; Fig. 3 A, B). In situ hybridization study revealed high-level PAI-1
Tubulointerstitial fibrosis was reduced in parallel with mRNA expression in CONT and TRX kidneys (Fig.
6 A, B). Strong PAI-1 mRNA signals were detectedglomerulosclerosis after treatment with TGL.
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Fig. 4. Glomerular cell proliferation. TGL alone or TGL 1 TRX treatment for 12 weeks significantly decreased glomerular cell proliferation
versus control (E). Staining for PCNA was not detected in the normal rat glomerulus (data not shown). There was a dramatic increase in PCNA
staining in the glomeruli in CONT (A) and TRX-treated rats (B) at 12 weeks after 5/6 Nx. TGL alone (C) or TGL 1 TRX treatment (D) markedly
reduced the PCNA-positive cells in glomeruli.
Fig. 5. p21 and p27 expression. p21 mRNA expression in glomeruli in
CONT (A, arrow) and TGL rats (B). p27 mRNA was expressed at a
diffuse, low level in glomeruli in CONT (C ) and TGL (D) rats. p27
protein was highly expressed in glomeruli in CONT (E ) and was de-
creased in TGL (F ). (G) TGL alone or TGL 1 TRX treatment for 12
weeks significantly decreased glomerular p27 protein expression versus
control.
primarily in sclerotic glomeruli and some tubules. Glo- or TGL 1 TRX vs. CONT, P , 0.05 and P , 0.01,
respectively; Fig. 7E). PAI-1 protein expression showedmerular visceral and parietal epithelial, mesangial, and
endothelial cells showed signal. PAI-1 mRNA expres- the same pattern as mRNA (Fig. 7 A-D).
sion was markedly reduced in TGL (Fig. 6C) and TGL 1
TGF-b1 mRNA expressionTRX-treated (Fig. 6D) rats compared with untreated
CONT rats. In situ hybridizations with sense probes In situ hybridization showed up-regulated TGF-b
mRNA in untreated CONT rat kidneys (both glomerulishowed no signal. PAI-1 protein expression in TGL and
TGL 1 TRX groups was also decreased compared with and tubules). The TGF-b signal appeared attenuated
after TGL treatment for 12 weeks (Fig. 8). Sense probesCONT (PAI-1 scoring: CONT 2.42 6 0.32, TRX 2.53 6
0.24, TGL 1.40 6 0.24, TGL 1 TRX 1.24 6 0.17; TGL showed no specific signal.
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Fig. 8. Transforming growth factor-b (TGF-b) mRNA expression byFig. 6. Plasminogen activator inhibitor-1 (PAI-1) mRNA expression.
in situ hybridization. TGF-b mRNA was up-regulated in glomerularIn situ hybridization for PAI-1 mRNA showed high expression in glo-
cells (A) and tubular epithelial cells (C) in CONT. TGF-b mRNAmeruli in CONT (A) and in TRX-treated rats (B), with signals detected
expression was attenuated after treatment with TGL for 12 weeks (Bprimarily in sclerotic glomeruli and some cortical tubules. PAI-1 mRNA
and D).expression was markedly diminished in rats treated with TGL alone
for 12 weeks (C) with trace signal in parietal epithelial cells. No PAI-1
mRNA was expressed in glomeruli in TGL 1 TRX-treated rats (D).
were also PPARg positive. In situ hybridization of rat
kidneys showed PPARg mRNA expression with the same
Modulation of glomerular macrophages distribution pattern as PPARg protein (Fig. 10 B, D, F).
At 12 weeks after 5/6 Nx, macrophages were present
in glomeruli of CONT and TRX-treated rats (macro-
DISCUSSIONphages/glomerulus: CONT 3.84 6 1.24, TRX 2.60 6 1.07,
P 5 NS; Fig. 9). Treatment with TGL alone or TGL 1 Progressive deterioration of the kidney is common to
TRX significantly reduced glomerular infiltrating macro- many renal diseases. The structural injury that leads to
phages (TGL 0.30 6 0.28, TGL 1 TRX 0.05 6 0.03, this progressive loss of function consists of glomerulo-
TGL or TGL 1 TRX vs. CONT, P , 0.05 and P , 0.01, sclerosis and tubulointerstitial fibrosis and atrophy.
respectively; Fig. 9). Many intervention strategies have been explored to slow
down or even reverse the progression of glomeruloscle-
PPARg expression rosis [40, 41]. In this study, to our knowledge for the first
time, we have demonstrated that PPARg agonist aloneImmunohistochemistry of rat tissue sections demon-
strated that PPARg was intensely expressed in the transi- can ameliorate the progression of glomerulosclerosis in
a nondiabetic, hypertensive glomerulosclerosis.tional epithelium of the ureter in all groups as previously
described (Fig. 10A) [21]. This staining thus served as Many studies have shown efficacy of TZD class agents
in diabetic vascular and renal lesions, linked to improveda positive internal control. PPARg was also expressed
diffusely in tubules in all rats. Double immunostaining glucose and lipid metabolism [7, 28, 32, 33]. However,
so far, studies have not examined PPARg agonist effectsfor both macrophages and PPARg demonstrated that
glomerular infiltrating macrophages did not express on nondiabetic glomerulosclerosis. The in vitro evidence
showing promotion of foamy macrophage transforma-PPARg, although resident glomerular cells (including
visceral, parietal epithelial cells, and mesangial cells) ex- tion by TGL suggested that this class of drugs might be
a dual-edged sword with underlying adverse effects topressed PPARg in CONT rats (Fig. 10C). Glomerular
visceral epithelial cells and tubular epithelial cells in promote atherosclerosis. Our current study shows the
efficacy of PPARg agonist to ameliorate the progressionCONT rats were PPARg positive, and these cell types
were also PCNA positive. Neither PPARg mRNA nor of glomerulosclerosis. The effect is independent of insu-
lin effects and could only be partially due to lipid effects,protein was detected in glomeruli of TGL or TGL 1
TRX-treated rats. Tubular PPARg expression was also as TGL treatment eliminated the significant but small
increase in cholesterol observed in the TRX group, andreduced in rats treated with TGL. TRX-treated rats ex-
pressed low levels of PPARg. In TGL or TGL 1 TRX plasma TG levels remained normal in all groups of rats.
Although blood pressure is an important factor associ-rats, there were no macrophages in glomeruli (Fig. 10E).
In contrast, macrophages in human carotid artery plaque, ated with progression [42], in this study, we observed
renoprotection with TGL that was independent of effectsstained as control, were identified by CD68 positivity and
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a return to baseline levels for p27 and sustained increase
for p21 [53]. Immune-mediated injury in the passive Hey-
mann nephritis model of membranous nephropathy is
associated with an increase in p21 and p27 levels, which
coincide with little if any proliferation [54]. However,
p21 has divergent functions. p21 can act as an assembly
factor of cdk4/cyclin D complexes or as an inhibitor of
CDK/cyclin [55, 56]. In mesangial cells in vitro, platelet-
derived growth factor (PDGF) causes a marked increase
of p21 protein [57]. The induction of p21 protein by
PDGF was also reported in p53-deficient as well as in
normal mouse fibroblasts, suggesting p53-independent
up-regulation of p21 by PDGF. Megyesi et al has recently
shown that lack of a functional p21 gene amelioratesFig. 9. Modulation of remnant glomerular macrophages. Treatment
with TGL alone or TGL 1 TRX significantly decreased glomerular progression to chronic renal failure [58]. They speculated
macrophage infiltration versus CONT. that p21 regulates the balance between hyperplasia and
hypertrophy after renal ablation, promoting hypertrophy
and sclerosis. We found highly expressed p21 and p27
in the glomeruli of untreated 5/6 Nx rats, thus suggestingon systemic hypertension. This indicates that additional
that there is active ongoing hypertrophy in these scleroticnonhemodynamic factors contribute to sclerosis, as we
kidneys. The decreased p21 mRNA expression and p27have extensively investigated previously [43–46].
protein in response to TGL indicate that these hypertro-These renal protective effects of PPARg agonist sug-
phic, prosclerotic mechanisms were dampened by TGL.gest that PPARg agonists may provide a novel interven-
Our results thus support a role for TGL, via PPARgtion strategy to prevent vascular and glomerular sclerosis.
activation, on cell cycle events and balance of prolifera-We hypothesize that the multiplicity of PPARg actions
tion and hypertrophy.may be due to its effects on several transcriptional fac-
Our study also showed that amelioration of glome-tors. These effects include cell cycle regulation, de-
rulosclerosis by PPARg agonist was linked to down-creased PAI-1 and TGF-b, and decreased macrophage
regulated PAI-1 expression. PAI-1, a member of theinfiltration.
superfamily of serine protease inhibitors, is a major phys-Abnormal cell growth with associated increased ma-
iological inhibitor of tissue-type plasminogen activatortrix accumulation is one of the important factors contrib-
(t-PA) and urokinase-type plasminogen activator (u-PA).
uting to the development of glomerulosclerosis. Cell pro-
These PAs activate plasminogen to plasmin and promote
liferation versus hypertrophy is controlled at the nuclear
fibrinolysis as well as proteolysis [59, 60]. Up-regulation
level by cyclin-dependent kinases (CDKs) and cyclin of PAI-1 can thus inhibit proteolysis of extracellular ma-
kinase inhibitors (CKIs) [47]. The latter inhibit cell pro- trix, leading to matrix accumulation and sclerosis. PAI-1
liferation by causing cell cycle arrest. p21CIP1/WAF1 and is linked to vascular sclerosis in both animal models and
p27kip1 belong to the CIP/Kip family of CKIs [48]. humans and is induced by angiotensin [40, 41]. PAI-1 is
One of the possible mechanisms for the beneficial ef- also increased in plasma of patients with insulin resis-
fects of PPARg agonist on sclerosis is the observed inhi- tance and is correlated with the severity of atherosclero-
bition of increased glomerular cell proliferation, which sis in such patients [61, 62]. In vitro, it was shown that
was associated with a low-level expression of p21 and TZDs decreased basal and tumor necrosis factor-a–
p27. Previous studies have suggested a role for PPARg stimulated PAI-1 expression in human umbilical vein
receptors in the control of cell proliferation, especially endothelial cells [27]. Recent data suggest that PPARg
in vascular smooth muscle cell (VSMC) proliferation and agonist inhibited gene transcription by antagonizing the
migration, which are critical events in the development activities of the transcription factors (TFs) activator pro-
of atherosclerosis and restenosis [49–51]. In the aortic tein-1 (AP-1) and nuclear factor-kB (NF-kB) [63]. The
balloon injury model in rats, TGL resulted in a signifi- PAI-1 promoter contains motifs for both these TFs
cantly less neointimal/media area ratio compared with [64, 65]. Thus, we speculate that down-regulation of PAI-1
control [52], which may relate to PPARg inhibition of mRNA expression may be mediated via a PPARg effect
early inflammatory/proliferation responses. on AP-1 and/or NF-kB–mediated transcriptional activity
Recent studies have shown that mesangial cell prolif- of PAI-1.
eration in the Thy-1 experimental glomerulonephritis Transforming growth factor-b is one of the key factors
model is associated with decreased p27 levels; the resolu- contributing to extracellular matrix accumulation and
glomerulosclerosis [66], and its inhibition can decreasetion of mesangial cell proliferation was associated with
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Fig. 7. PAI-1 expression detected by immunostaining. TGL alone or TGL 1 TRX treatment for 12 weeks significantly reduced glomerular PAI-1
expression versus control (E ). PAI-1 was highly expressed in glomeruli in CONT (A) and in TRX (B), associated with sclerotic lesions; PAI-1
protein was only weakly expressed in some glomerular parietal epithelial cells in TGL group (C). There was only trace PAI-1 expression in
glomeruli in the TGL 1 TRX (D) group.
matrix accumulation [67]. In this study, we observed
up-regulated TGF-b mRNA in CONT rats, and TGL
diminished this TGF-b mRNA expression. These results
suggest that beneficial effects of TGL on sclerosis may
occur through inhibition of both PAI-1 and TGF-b, thus
augmenting matrix turnover and decreasing matrix syn-
thesis.
An additional finding in this study was the lack of
PPARg expression in macrophages infiltrating glomer-
uli. Monocytes and macrophages play an important role
in immune and nonimmune chronic sclerosing renal dis-
eases [68–70]. Activated macrophages are a rich source
of growth factors, cytokines, vasoactive substances, pro-
teolytic enzymes, and reactive oxygen species (ROS) [71].
Decreased ROS-related injury caused by decreased mac-
rophages may thus have contributed to amelioration of
sclerosis by TGL. Additionally, the antioxidant moiety of
TGL may have decreased oxidant injury directly [72, 73].
These infiltrating macrophages did not express PPARg,
although glomerular-resident cells (glomerular visceral,
parietal epithelial cells, and mesangial cells) did show
increased PPARg expression in the untreated 5/6 Nx
rats. Our results indicate that there is a phenotypic diver-
sity of macrophages in glomerular versus vascular sclero-
sis. Macrophages in human atherosclerotic carotid artery
plaques did express PPARg and are thought to promote
Fig. 10. Detection of PPARg and macrophages. Transitional epithelial foam cell transformation and plaque formation [74]. Be-cells of pelvis, which express PPARg, served as a positive control (A).
cause glomerular resident cells contribute actively to glo-Carotid artery plaque, another positive control, showed PPARg-posi-
tive, CD68-positive macrophages (data not shown). Double immuno- merulosclerosis [41], our results also suggest that glomer-
staining showed that glomerular infiltrating macrophages (C, red, arrow- ular intrinsic cells are a target of PPARg agonist. PPARghead) did not express PPARg, although glomerular cells did show
expressed in these glomerular cells may act to counter-increased PPARg expression (C, brown, arrow). There was no detect-
able PPARg in glomeruli in TGL rats (E ). In situ hybridization showed balance the existing overwhelming proinflammatory and
that PPARg mRNA expression had similar distribution as PPARg prosclerotic effects. A reduction of glomerular macro-receptor protein expression [(D), CONT and (F ), TGL]. Ureteral epi-
thelium, which expresses PPARg, served as a positive control (B). phages by TGL treatment in our study could reflect
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retinoic X receptor; SI, sclerosis index; SPB, systolic blood pressure;TGL’s effects in inflammation regulation. Possible mech-
TF, transcription factor; TGF-b, transforming growth factor-b; TGL,
anisms include TGL inhibition of expression of vascular troglitazone group; TNF-a, tumor necrosis factor-a; t-PA tissue-type
cell adhesion molecule-1 (VCAM-1) and intercellular plasminogen activator; TRX, triple antihypertensive drug therapy group;
TZDs, thiazolidinediones; VCAM-1, vascular cell adhesion molecule-1;adhesion molecule-1 (ICAM-1) in endothelial cells, re-
VSMC, vascular smooth muscle cell; u-PA, urokinase-type plasmino-sulting in significantly reduced monocyte/macrophage gen activator.
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